Active Clinical Trials for Prostate Cancer


This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
11/19/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
12/10/2013IRB13846/13-846Elias Obeid Genetic Evaluation Of Men - The GEM Registry
08/04/201414-036/14-036Marc Smaldone SURG-073: A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Elective Major Cancer Surgery ("Perioperative Risk Study")
01/02/201815-1009/15-1009Anthony Olszanski A Phase I Dose-Escalation Study of ONC201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
05/15/201515-9018/15-9018Marc Smaldone Pennsylvania Urologic Regional Collaborative
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
01/01/201815-8013/15-8013Suzanne Miller Improving Decision-Making for Low Health Literate Prostate Cancer Patients
01/13/201716-1043/16-1043Alexander Kutikov REASSURE ME
07/07/201716-1071/16-1071Anthony Olszanski A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
05/06/201615-1081/15-1081Wafik El-Deiry A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
12/01/201515-1015/15-1015Daniel Geynisman Bicalutamide with or without Metformin for Biochemical Recurrence in Prostate Cancer Patients (BIMET-1)
07/28/201515-9022/15-9022Eric Horwitz Short term complications in prostate brachytherapy, active surveillance, and prostatectomy.
12/13/201717-1051/17-1051Anthony Olszanski A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects with Advanced Solid Tumors
05/30/201818-9017/18-9017Eric Horwitz A Multi-institutional, Propensity Score-matched Comparison of Moderately Hypofractionated Photon and Proton Therapy for Localized Prostate Cancer
05/17/201818-2007/18-2007Alvaro Pereira-Rico Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial
05/29/201818-1021/18-1021Elizabeth Plimack Phase II Study of Front Line Therapy with Nivolumab and Salvage Nivolumab + Ipilimumab in Patients with Advanced Renal Cell Carcinoma HCRN: GU16-260
05/30/201818-9015/18-9015Shannon Lynch Multilevel Precision-Based Approach to Prostate Disparities: Geographic Analyses
05/30/201716-1101/16-1101Anthony Olszanski A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies
06/23/201717-1008/17-1008Daniel Geynisman A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prenisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
11/16/201717-2003/17-2003Mark Sobczak Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel
06/02/201717-9020/17-9020Jessica Bauman Frequency of End of Life Discussions in Oncology Fellow Clinics at Fox Chase Cancer Center
11/21/201717-1042/17-1042Anthony Olszanski A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination with Palliative Radiotherapy in Subjects with Solid Tumors
12/27/201717-1046/17-1046Jessica Bauman A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 (anti-ICOS mAb) Alone or in Combination with Nivolumab or Ipilimumab in Patients with Advanced Solid Tumors
04/12/201817-1047/17-1047Anthony Olszanski Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10c796 T in HLA-A2+ Subjects with MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors.